胰腺导管腺癌对吉西他滨耐药研究现状及展望  

Current status and prospects of gemcitabine resistance in pancreatic ductal adenocarcinoma

作　　者：殷晓煜[1] 石殷浩 Yin Xiaoyu;Shi Yinhao(Department of Pancreato-Biliary Surgery,the First Affiliated Hospital of Sun Yat-Sen University,Guangzhou 510080,China)

机构地区：[1]中山大学附属第一医院胆胰外科,广州510080

出　　处：《中华实验外科杂志》2024年第12期2687-2693,共7页Chinese Journal of Experimental Surgery

摘　　要：胰腺导管腺癌是一种具有高度侵袭性的消化系统恶性肿瘤。在全球范围内, 其发病率和死亡率均呈现逐年上升的趋势, 患者的五年生存率不足10%。尽管手术切除是目前公认的唯一可能实现胰腺导管腺癌根治的手段, 但是多数患者在确诊时已处于晚期, 错失了手术的最佳时机。吉西他滨作为胰腺导管腺癌治疗的一线化疗药物, 在临床上得到了广泛应用, 但其耐药问题日益严重, 极大制约了其治疗效果及患者预后的改善。本文作者结合自身团队的研究成果, 系统回顾分析了胰腺导管腺癌对吉西他滨产生耐药性的分子机制, 并在此基础上深入探讨了多种逆转胰腺导管腺癌耐药的策略。本研究不仅为胰腺导管腺癌的综合治疗提供了新的理论视角, 还揭示了若干具有临床应用前景的治疗靶点, 有望为胰腺导管腺癌患者的治疗开辟新的途径。Pancreatic ductal adenocarcinoma(PDAC)is a highly aggressive malignant tumor of the digestive system.The morbidity and mortality rates are on the rise year by year,and the five-year survival rate of patients is less than 10%.Despite the current recognition of surgical resection as the only potentially curative treatment for PDAC,the majority of patients are diagnosed at an advanced stage,missing the best opportunity for surgical intervention.Gemcitabine,a first-line chemotherapy drug for PDAC,has been widely used in clinical practice,but the emerging issue of drug resistance severely limits its therapeutic efficacy and the improvement of patients’prognoses.In this article,we systematically reviewed and analyzed the molecular mechanism of gemcitabine resistance in PDAC combined with the research findings of our team,and on the basis of which,we thoroughly explored multiple strategies for reversing gemcitabine resistance in PDAC.This study not only provides a new theoretical perspective for the comprehensive treatment of PDAC,but also reveals a number of therapeutic targets with clinical application prospects,which is expected to open up novel options for the treatment of PDAC.

关 键 词：胰腺导管腺癌 吉西他滨耐药 治疗策略 

分 类 号：R735.9[医药卫生—肿瘤]